erlotinib hydrochloride has been researched along with trifluoperazine in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (trifluoperazine) | Trials (trifluoperazine) | Recent Studies (post-2010) (trifluoperazine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,696 | 157 | 198 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | trifluoperazine (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.7 | ||
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | 8 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Lysozyme C-1 | Rattus norvegicus (Norway rat) | 9 | |
| Beta-glucuronidase | Rattus norvegicus (Norway rat) | 7.8 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.75 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 6.226 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | 1.4 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.35 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.016 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 6.226 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 6.226 | |
| WD repeat-containing protein 48 | Homo sapiens (human) | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Brell, M; Fernández de Mattos, S; Ramis, G; Serra-Sitjar, M; Villalonga, P; Villalonga-Planells, R | 1 |
2 other study(ies) available for erlotinib hydrochloride and trifluoperazine
| Article | Year |
|---|---|
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Box Protein O3; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; Transcriptional Activation; Trifluoperazine | 2019 |